Barclays Maintains Overweight on McKesson, Raises Price Target to $1235
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $1000 to $1235.
Last updated: 2026-11-18 15:09:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
McKesson Corporation (MCK) operates in the WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES sector and is listed on NYSE. The stock is currently priced at $1,079.26, with a market capitalization of $127.58B and a P/E ratio of 26.82. Over the past 52 weeks, its price has ranged from $723.68 to $1,121.50. This page covers its latest market performance, valuation, price trends and company information.
$127.58B | |
$1,083.34 | |
$1,102.29 | |
$1,075.72 | |
$1,091.67 | |
62.31K | |
802.97K | |
26.82 | |
$1,121.50 | |
$723.68 | |
0.32% | |
2026-09-30 |
McKesson Corporation (MCK) is currently trading at $1,079.26 as of 2026-11-18 14:52:54, down 0.93% ($10.17) from the previous close of $1,091.67
During today's regular trading session, MCK has traded between $1,075.72 and $1,102.29, with a trading volume of 62.31K shares. The current price is near the lower end of today's range.
Over the past seven days, McKesson Corporation (MCK) moved from $1,059.37 to $1,079.26, representing a gain of 1.88% ($19.89).
The stock traded between $1,055.73 and $1,118.01 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 608.59 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 89.4%
MCK is currently trading at $1,079.26, placing it 89.4% of the way from its 52-week low of $723.68 to its 52-week high of $1,121.50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
| Industry | WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES |
| Employees | 43,000 |
| CEO | Brian S. Tyler |
| Founded | 1833 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for McKesson Corporation.
Dividend | |
|---|---|
| Ex-Dividend Date | Dec 1, 2026 |
| Payment Date | Jan 4, 2027 |
| Dividend Per Share | $0.94 |
Latest news related to McKesson Corporation and MCK stock.
Barclays analyst Glen Santangelo maintains McKesson (NYSE:MCK) with a Overweight and raises the price target from $1000 to $1235.
McKesson (NYSE:MCK) has outperformed the market over the past 15 years by 6.37% on an annualized basis producing an average annual return of 19.38%. Currently, McKesson has a market capitalization of $128.58 billion.
McKesson (MCK), a prescription drug distributor, has gained 12.6% over the past month, outperforming the S&P 500's -3.7% decline. The company has a Zacks Rank #2 (Buy) rating based on positive earnings estimate revisions. Current quarter EPS is expected at $10.79 (+15.5% YoY), with full-year earnings projected at $45.78 (+17.1% YoY). Revenue growth is forecasted at 8% for the current quarter and fiscal year. McKesson has consistently beaten consensus estimates and trades at a valuation discount to peers (Value Style Score: B).
The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.
Eligible investors can buy real shares of McKesson Corporation (MCK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MCK, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MCK shares and USD.
MCK Shares to USD
1.00 MCK shares = 1,079.256 USD
Calculations are estimates based on the latest available price and are for reference only.